Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

References

• Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: european academy of allergology and clinical immunology/American Academy of allergy, asthma and immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2006;118(1):1–8. doi: 10.1016/j.jaci.2006.03.045.
   Web of Science ®Google Scholar
• Lee SY, Lee E, Park YM, et al. Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(4):354–362. doi: 10.4168/aair.2018.10.4.354.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.
   PubMed Web of Science ®Google Scholar
• Laughter M, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi: 10.1111/bjd.19580.
   PubMed Web of Science ®Google Scholar
• Legat FJ. Itch in atopic dermatitis - What is new? Front Med . 2021;8:644760. doi: 10.3389/fmed.2021.644760.
   Web of Science ®Google Scholar
• Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142–152. Jandoi: 10.1111/jdv.15919.
   PubMed Web of Science ®Google Scholar
• Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a 2-way street? J Allergy Clin Immunol. 2018; 142(4):1033–1040. doi: 10.1016/j.jaci.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347. doi: 10.1016/j.anai.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25. doi: 10.1016/j.jid.2016.08.022.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019; 29(3):250–258. doi: 10.1684/ejd.2019.3557.
   PubMed Web of Science ®Google Scholar
• Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821–838. doi: 10.1007/s40257-018-0383-4.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic ­therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345.
   PubMed Web of Science ®Google Scholar
• European Medicines A. EMA/505843/2020: an overview of olumiant and why it is authorised in the EU. Amsterdam: European Medicines Agency; 2017.
   Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343. doi: 10.1001/jamadermatol.2020.3260.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898.
   PubMed Web of Science ®Google Scholar
• Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338–352. Sepdoi: 10.1111/bjd.21630.
   PubMed Web of Science ®Google Scholar
• Steinke S, Langenbruch A, Ständer S, et al. Therapeutic benefits in atopic dermatitis care from the patients” perspective: results of the German national health care study “atopic health. Dermatology. 2014;228(4):350–359. doi: 10.1159/000358587.
   PubMed Web of Science ®Google Scholar
• Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36. doi: 10.1186/1477-7525-7-36.
   PubMed Web of Science ®Google Scholar
• Hall R, Lebwohl MG, Bushmakin AG, et al. Development and content validation of pruritus and symptoms assessment for atopic dermatitis (PSAAD) in adolescents and adults with moderate-to-severe AD. Dermatol Ther . 2021;11(1):221–233. doi: 10.1007/s13555-020-00474-9.
   Web of Science ®Google Scholar
• Paul C, Griffiths CEM, Costanzo A, et al. Factors predicting quality of life impairment in adult patients with atopic dermatitis: results from a patient survey and machine learning analysis. Dermatol Ther . 2023;13(4):981–995. doi: 10.1007/s13555-023-00897-0.
   Web of Science ®Google Scholar
• Thyssen JP, de Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40(8):3574–3587. In Press. doi: 10.1007/s12325-023-02528-8.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Papp K, Forman S, et al. The contribution of itch and skin severity improvements to the dermatology life quality index in patients with atopic dermatitis in baricitinib phase III trials. Br J Dermatol. 2022;186(6):1047–1049. doi: 10.1111/bjd.21015.
   PubMed Web of Science ®Google Scholar
• Oosterhaven JAF, Spekhorst LS, Zhang J, et al. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry. J Dermatolog Treat. 2022;33(4):1986–1989. doi: 10.1080/09546634.2021.1937485.
   PubMed Web of Science ®Google Scholar
• Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381–388 e2. doi: 10.1016/j.anai.2019.07.008.
   PubMed Web of Science ®Google Scholar